Your session is about to expire
← Back to Search
Stem Cell Therapy
Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD
Phase 1 & 2
Waitlist Available
Research Sponsored by Regenerative Patch Technologies, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new treatment using special cells on a thin film to help patients with severe vision loss from advanced dry AMD. The cells are implanted into the eye to repair and support damaged tissue, potentially slowing or stopping further vision loss. Recent studies have shown the potential of this approach in repairing the degenerated retina in AMD.
Eligible Conditions
- Macular Degeneration
- Age-Related Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Frequency and Severity of Treatment-Related Adverse Events [Safety and Tolerability]
Secondary study objectives
Photoreceptor Electrical Responses
Visual Acuity
Visual Field
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CPCB-RPE1 treatmentExperimental Treatment1 Intervention
Subretinal implantation of CPCB-RPE1 in dry AMD patients
Find a Location
Who is running the clinical trial?
Regenerative Patch Technologies, LLCLead Sponsor
1 Previous Clinical Trials
24 Total Patients Enrolled
1 Trials studying Macular Degeneration
24 Patients Enrolled for Macular Degeneration
Jane Lebkowski, Ph.D.Study DirectorRegenerative Patch Technologies